Try our Advanced Search for more refined results
Life Sciences
- 
									September 18, 2025
									Japanese Glycine Exporter Hit With 86% Antidumping DutyThe U.S. Department of Commerce issued a notice Thursday indicating a Japanese supplier of glycine faces a more than 86% antidumping duty rate, saying the company failed to cooperate with the federal government's investigation. 
- 
									September 18, 2025
									Group Of US Investors To Buy TikTok, Plus More RumorsA consortium of big-name buyers including Oracle, Silver Lake and Andreessen Horowitz are rumored to be taking a majority stake in TikTok after a long search to find the app a U.S. owner; Paramount Skydance is reportedly ready to make an offer for Warner Bros. Discovery; and private equity shop CVC is close to inking a $1.5 billion deal to acquire web-hosting provider Namecheap. Here, Law360 breaks down these and other deal rumors from the past week. 
- 
									September 18, 2025
									Valitic Soap Is Unapproved Drug, Class Of Buyers ClaimsA proposed class of soap buyers is suing the maker of Valitic soap in New York federal court, alleging that it is an illegal drug as it claims to be able to treat dark spots, acne and other skin conditions without U.S. Food and Drug Administration approval. 
- 
									September 17, 2025
									J&J Whistleblowers Defend $1.6B False Claims Act WinWhistleblowers filed a brief Wednesday in the Third Circuit in a closely watched False Claims Act appeal involving a $1.6 billion judgment against Johnson & Johnson unit Janssen as well as the constitutionality of the FCA's "qui tam" whistleblower provisions, arguing that the act's lawfulness has been settled by its "unbroken 162-year history." 
- 
									September 17, 2025
									Chancery Mulls Limited Discovery In $8.7B Cerevel Sale SuitA Delaware vice chancellor said Wednesday he is considering denial of a motion to dismiss as well as limited plaintiff discovery in a suit accusing Cerevel Therapeutics Holdings Inc. insiders of lining up a secondary stock sale ahead of the biopharma's disclosure of a proposed $8.7 billion sale to AbbVie. 
- 
									September 17, 2025
									FDA Says Vape Manufacturer Lying About Marketing ApprovalThe U.S. Food and Drug Administration on Tuesday sued manufacturers of flavored vapes in New Jersey federal court to seek an end to their sales, saying that they are falsely representing that their products had received marketing approval. 
- 
									September 17, 2025
									Don Jr.-Backed Patent Co. Hires Nokia Licensing ExecSIM IP, the newest venture by high-profile patent monetizer Erich Spangenberg, has brought on Nokia's chief licensing officer to serve as managing director. 
- 
									September 17, 2025
									Missouri AG Can Seek Unredacted Trans Care RecordsThe Missouri attorney general can demand that a hospital turn over unredacted records on patients getting transgender care as part of a probe of a whistleblower complaint, a state appeals court held Tuesday. 
- 
									September 17, 2025
									Ex-CDC Head Says RFK Jr. Urged Vax Schedule Rubber StampSusan Monarez, the former head of the Centers for Disease Control and Prevention, told federal lawmakers on Wednesday she was abruptly fired just weeks into her tenure for "holding the line on scientific integrity." 
- 
									September 17, 2025
									Purdue Can Pay CEO Ch. 11 Bonus After Trimming CompA New York bankruptcy judge Wednesday approved a nearly $3 million incentive program for Purdue Pharma's chief executive after he agreed to reduce his total compensation by $500,000. 
- 
									September 16, 2025
									Exactech Enters $8M Deal To Resolve Implant Failure ClaimsOrthopedic implant-maker Exactech Inc. agreed to pay $8 million to resolve allegations it marketed and sold faulty components of its knee-replacement systems that were to be used on patients on Medicare, Medicaid and U.S. Department of Veterans Affairs assistance, federal prosecutors in Maryland and Alabama announced Tuesday. 
- 
									September 16, 2025
									Merck Says Vaccine Case 'Poor Vehicle' For Antitrust ReviewMerck & Co. told the U.S. Supreme Court to reject a bid from physicians looking to revive antitrust claims over submissions the pharmaceutical giant made to federal regulators concerning its mumps vaccine, arguing that the case is "an exceptionally poor vehicle" for review. 
- 
									September 16, 2025
									BrainStorm Can't Shed Investors' ALS Treatment Trial ClaimsBiopharmaceutical company BrainStorm Cell Therapeutics Inc. must face a proposed investor class alleging it misrepresented feedback from the U.S. Food and Drug Administration regarding clinical trials for an ALS product candidate that failed to get approval, though a Manhattan federal judge has tossed the suit's insider trading allegations and certain fraud claims. 
- 
									September 16, 2025
									The Patent Workforce Is Attracting Fewer Attys, More AgentsThe pool of patent practitioners registered with the U.S. Patent and Trademark Office has undergone a dramatic shift over the past few decades, with the number of attorneys taking the bar exam decreasing at the same time more patent agents are entering the field. 
- 
									September 16, 2025
									Jazz Can't Escape Antitrust Claims Over Sleep Disorder IPA Delaware federal judge has refused to let Jazz Pharmaceuticals dodge antitrust claims that it wrongly listed a patent covering a way to distribute a narcolepsy drug in the U.S. Food and Drug Administration's Orange Book. 
- 
									September 16, 2025
									CVS Caremark Takes $290M Overbilling Judgment To 3rd Circ.CVS's pharmacy benefits manager will appeal a judgment against the company that was recently increased from $95 million to $290 million in a suit alleging it overbilled Medicare Part D-sponsored drugs, according to a notice of appeal filed in Pennsylvania federal court. 
- 
									September 16, 2025
									FTC Chair Pledges 'Action' Against Late Merger FixesFederal Trade Commission Chairman Andrew Ferguson vowed Tuesday to take unspecified "action" against tactics by merging companies to propose fixes only after antitrust enforcers bring a transaction challenge, a strategy he called "bad for the system." 
- 
									September 16, 2025
									Jones Day Adds FDA Regulatory Expert As Of Counsel In DCJones Day on Tuesday announced the arrival of an attorney who brings over a decade of experience at the U.S. Food and Drug Administration advising on drug regulation. 
- 
									September 16, 2025
									For Cahill Atty, Rare Disease Pro Bono Work Is PersonalJohn MacGregor of Cahill Gordon & Reindel LLP didn't have any experience in healthcare law before taking on a pro bono client that supports people with a rare form of epilepsy. MacGregor's son is one of them. 
- 
									September 16, 2025
									VarmX Partners With Biotech CSL In Deal Worth Up To $2.2BEuropean life sciences venture capital firm EQT Life Sciences on Tuesday announced that its portfolio company VarmX, a Netherlands-based biotech, has entered into an exclusive option agreement to be bought by global biotech CSL in a deal worth up to $2.2 billion. 
- 
									September 15, 2025
									Jazz Loses Bid To Block Avadel From Seeking Sleep Drug OKJazz Pharmaceuticals Inc. cannot block Avadel CNS Pharmaceuticals LLC from seeking U.S. Food and Drug Administration approval for its sleep disorder treatment, a Delaware federal judge ruled, saying the act of seeking FDA approval is not an infringing activity that can be enjoined. 
- 
									September 15, 2025
									AbbVie Settles Rinvoq Litigation, Blocks Generics Until 2037AbbVie Inc. has settled litigation with drug manufacturers, blocking generic versions of its immunosuppressant Rinvoq drug from the market for just over a decade and closing out litigation that accused generic-drug makers of infringing a slew of its patents. 
- 
									September 15, 2025
									Ch. 11 Plan Faces Blowback From 23andMe Breach ClaimantsMore than 30,000 individuals who elected to pursue arbitration rather than sign on to a proposed class settlement over a data breach at 23andMe are urging a Missouri bankruptcy judge to reject the DNA testing company's notice of its reorganization plan, arguing that the disclosure provides misleading and inflated information about the company's agreement with these claimants. 
- 
									September 15, 2025
									Bayer Urges 9th Circ. Not To Revive Tevra Flea, Tick Meds SuitBayer is urging the Ninth Circuit not to grant a new trial over claims that it locked up the market for pet flea and tick treatment, saying the only evidence that rival Tevra showed a jury at trial was "highly dubious." 
- 
									September 15, 2025
									Ex-PTAB Leader Reflects On USPTO After Leaving AgencyOne of the Patent Trial and Appeal Board's most senior judges has left the U.S. Patent and Trademark Office after more than 13 years, and soon after joining private practice she spoke with Law360 about her history at the agency and the current dynamics playing out at the office. 
Expert Analysis
- 
								
								Tips For Litigating Apex Doctrine Disputes Amid Controversy  Litigants once took for granted that deposition requests of high-ranking corporate officers required a greater showing of need than for lower-level witnesses, but the apex doctrine has proven controversial in recent years, and fights over such depositions will be won by creative lawyers adapting their arguments to this particular moment, say attorneys at Hangley Aronchick. 
- 
								Series Performing As A Clown Makes Me A Better Lawyer  To say that being a clown in the Macy’s Thanksgiving Day Parade has changed my legal career would truly be an understatement — by creating an opening to converse on a unique topic, it has allowed me to connect with clients, counsel and even judges on a deeper level, says Charles Tatelbaum at Tripp Scott. 
- 
								
								A Midyear Tuneup For Your Trade Secret Portfolio  Halfway through 2025, now is a good time for companies to thoroughly evaluate their trade secret portfolios and follow eight steps to reassess protection processes for confidential information, says Robert Jensen at Wolf Greenfield. 
- 
								
								Focusing On Fluoride: From FDA To Class Action  A class action filed two days after the U.S. Food and Drug Administration announced plans to remove ingestible fluoride prescription drug products for children from the market may be the tip of the iceberg in terms of the connection between government pronouncements on safety and their immediate use as evidence in lawsuits, says Rachel Turow at Skadden. 
- 
								Series Law School's Missed Lessons: Rejecting Biz Dev Myths  Law schools don’t spend sufficient time dispelling certain myths that prevent young lawyers from exploring new business opportunities, but by dismissing these misguided beliefs, even an introverted first-year associate with a small network of contacts can find long-term success, says Ronald Levine at Herrick Feinstein. 
- 
								
								Move Beyond Surface-Level Edits To Master Legal Writing  Recent instances in which attorneys filed briefs containing artificial intelligence hallucinations offer a stark reminder that effective revision isn’t just about superficial details like grammar — it requires attorneys to critically engage with their writing and analyze their rhetorical choices, says Ivy Grey at WordRake. 
- 
								
								Observations On 5 Years Of Non-Notified CFIUS Inquiries  Since 2020, the Committee on Foreign Investment in the United States has identified and investigated covered cross-border transactions not formally notified to CFIUS, and a look at data from 50 non-notified matters during that time reveals the general dynamics of this enforcement function, say attorneys at Cooley. 
- 
								
								9th Circ. Has Muddied Waters Of Article III Pleading Standard  District courts in the Ninth Circuit continue to apply a defunct and especially forgiving pleading standard to questions of Article III standing, and the circuit court itself has only perpetuated this confusion — making it an attractive forum for disputes that have no rightful place in federal court, say attorneys at Gibson Dunn. 
- 
								
								An Underused Tariff Exemption For Medical Product Importers  Medical device importers may be able to reduce tariff exposure by leveraging an often-overlooked Nairobi Protocol duty exemption for products specially designed to benefit those with qualifying medical conditions, says Samuel Finkelstein at LMD Trade Law. 
- 
								Series Competing In Modern Pentathlon Makes Me A Better Lawyer  Opening myself up to new experiences through competing in modern Olympic pentathlon has shrunk the appearance of my daily work annoyances and helps me improve my patience, manage crises better and remember that acquiring new skills requires working through your early mistakes, says attorney Mary Zoldak. 
- 
								
								Prepare For Increased FDA Inspections Of Foreign Facilities  In light of the U.S. Food and Drug Administration's recently announced plans to expand use of unannounced inspections of foreign drug manufacturing factories, foreign firms should implement best practices in anticipation of an imminent increase in enforcement activity, say attorneys at McGuireWoods. 
- 
								Series Law School's Missed Lessons: Teaching Yourself Legal Tech  New graduates often enter practice unfamiliar with even basic professional software, but budding lawyers can use on-the-job opportunities to both catch up on technological skills and explore the advanced legal and artificial intelligence tools that will open doors, says Alyssa Sones at Sheppard Mullin. 
- 
								
								Navigating Potential Sources Of Tariff-Related Contract Risk  As the tariff landscape continues to shift, companies must anticipate potential friction points arising out of certain common contractual provisions, prepare to defend against breach claims, and respond to changing circumstances in contractual and treaty-based relationships, say attorneys at Debevoise. 
- 
								
								How AI May Reshape The Future Of Adjudication.png)  As discussed at a recent panel at Texas A&M, artificial intelligence will not erase the human element of adjudication in the next 10 to 20 years, but it will drive efficiencies that spur private arbiters to experiment, lead public courts to evolve and force attorneys to adapt, says Christopher Seck at Squire Patton. 
- 
								
								When Legal Advocacy Crosses The Line Into Incivility  As judges issue sanctions for courtroom incivility, and state bars advance formal discipline rules, trial lawyers must understand that the difference between zealous advocacy and unprofessionalism is not just a matter of tone; it's a marker of skill, credibility and potentially disciplinary exposure, says Nate Sabri at Perkins Coie.